Professor Helmout Modjtahedi
Faculties, deparments and locations
- Faculty of Health, Science, Social Care and Education
- Department of Biomolecular Sciences
- School of Life Sciences, Pharmacy and Chemistry
- Penrhyn Road
Professor of Cancer Biology
- Email:
- h.modjtahedi@kingston.ac.uk
About
After receiving my degree in Medical Laboratory Science from the University of Ulster in 1989, I completed my PhD in Tumour Immunology at the Institute of Cancer Research/University of London in 1993.
Subsequently, I worked as a Postdoctoral Research Fellow at the Institute of Cancer Research/University of London (1993-1999) and was appointed to a Clinical Lectureship in Pharmaco-Immunology/Tumour Immunology at the European Institute of Health and Medical Sciences/Postgraduate Medical School at the University of Surrey (1999-2007).
I moved to the School of Life Sciences at Kingston University as Senior Lecturer in 2001 and became a Reader in 2007. In 2012, I was promoted to Professor of Cancer Biology. I currently teach a range of undergraduate and postgraduate bioscience programmes, with a particular focus on cancer-related subjects, and lead an active research group. In my laboratory, we particularly focus on cancer biology, therapeutics, and diagnostics.
Qualifications
- Certificate
- PhD, Tumour Immunology, Institute of Cancer Research, University of London
- First Class BSc Honours in Medical Laboratory Science, University of Ulster
Domains
My research expertise is translational cancer research. My research activities to date focus on four key areas:
- Studying the biological and clinical significance and targeting of growth factor receptors with tyrosine kinase activities in human cancers and other pathological conditions.
- Development of monoclonal antibody (mAb)-based products for use in cancer diagnosis and therapy.
- Predictive biomarkers for poor response to therapy with monoclonal antibodies and/or small molecule tyrosine kinase inhibitors in cancer.
- Discovery of overexpressed tumour antigens using monoclonal antibody-based technology.
Publications
Development and characterization of three novel FGFR inhibitor resistant cervical cancer cell lines to help drive cervical cancer research
Bou Antoun, Nauf, Afshan Mahmood, Hiba-Tun-Noor, Walker, Anthony J., Modjtahedi, Helmout, Grose, Richard P. and Chioni, Athina-Myrto, 2025, International Journal of Molecular Sciences (26), 5, pp 1799
Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma
Sherif, Ozlem, Khelwatty, Said, Bagwan, Izhar, Seddon, Alan, Dalgleish, Angus, Mudan, Satvinder and Modjtahedi, Helmout, 2024, Oncology Reports (52), 6, pp 172
The combination of afatinib with dasatinib or miransertib results in synergistic growth inhibition of stomach cancer cells
Al-Janaby, Tina, Nahi, Narmin, Seddon, Alan, Bagwan, Izhar, Khelwatty, Said and Modjtahedi, Helmout, 2024, World Journal of Oncology (15), 2, pp 192-208
The co-expression of HER family members and CD109 is common in pancreatic cancer
Khan, Tanzeel, Seddon, Alan, Khelwatty, Said, Dalgleish, Angus, Bagwan, Izhar, Mudan, Satvinder and Modjtahedi, Helmout, 2023, Medical Research Archives (11), 11
Description of PTPRG genetic variants identified in a cohort of Chronic Myeloid Leukemia patients and their ability to influence response to Tyrosine kinase Inhibitors
Ismail, Mohamed A., Nasrallah, Gheyath K., Monne, Maria, AlSayab, Ali, Yassin, Mohamed A., Varadharaj, Govindarajulu, Younes, Salma, Sorio, Claudio, Cook, Richard, Modjtahedi, Helmout and Al-Dewik, Nader, 2022, Gene (813), pp 146101
Cytokine/chemokine release patterns and transcriptomic profiles of LPS/IFNγ-activated human macrophages differentiated with heat-killed 'Mycobacterium obuense', M-CSF, or GM-CSF
Bazzi, Samer, El-Darzi, Emale, McDowell, Tina, Modjtahedi, Helmout, Mudan, Satvinder, Achkar, Marcel, Akle, Charles, Kadara, Humam and Bahr, Georges M., 2021, International Journal of Molecular Sciences (22), 13, pp 7214
Predictive value of tyrosine phosphatase receptor gamma for the response to treatment tyrosine kinase inhibitors in chronic myeloid leukemia patients.
Ismail, Mohamed A., Vezzalini, Marzia, Morsi, Hisham, Abujaber, Ahmad, Al Sayab, Ali, Siveen, Kodappully, Yassin, Mohamed A., Monne, Maria, Samara, Muthanna, Cook, Richard, Sorio, Claudio, Modjtahedi, Helmout and Al-Dewik, Nader I., 2021, Scientific Reports (11), pp 8833
Therapeutic application of monoclonal antibodies in pancreatic cancer : advances, challenges and future opportunities
A. Arias-Pinilla, Gustavo and Modjtahedi, Helmout, 2021, Cancers (13), 8, pp e1781
HER2 expression is predictive of survival in cetuximab treated patients with RAS wild type metastatic colorectal cancer
Khelwatty, Said A., Puvanenthiran, Soozana, Essapen, Sharadah, Bagwan, Izhar, Seddon, Alan M. and Modjtahedi, Helmout, 2021, Cancers (13), 4, pp e638
Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations : implications for future clinical trials in pancreatic cancer
Khan, Tanzeel, Seddon, Alan M., Dalgleish, Angus G., Khelwatty, Said, Ioannou, Nikolaos, Mudan, Satvinder and Modjtahedi, Helmout, 2020, Oncology Reports (44), 6, pp 2581-2594
Aberrant DNA methylation of PTPRG as one possible mechanism of its under-expression in CML patients in the state of Qatar
Ismail, Mohamed A., Samara, Muthanna, Al Sayab, Ali, Alshashani, Mohamed, Yassin, Mohamed A., Varadharaj, Govindaraiulu, Vezzalini, Mariza, Tomasello, Luisa, Monne, Maria, Morsi, Hisham, Qoronfleh, M. Walid, Zayed, Hatem, Cook, Richard, Sorio, Claudio, Modjtahedi, Helmout and Al-Dewik, Nader I., 2020, Molecular Genetics and Genomic Medicine (8), 10, pp e1319
Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer
Arias-Pinilla, Gustavo A., Dalgleish, Angus G., Mudan, Satvinder, Bagwan, Izhar, Walker, Anthony J. and Modjtahedi, Helmout, 2020, Scientific Reports (10), pp 537
Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan M. and Modjtahedi, Helmout, 2019, Oncotarget (10), 18, pp 1704-1715
Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer
Puvanenthiran, S., Essapen, S., Haagsma, B., Bagwan, I., Green, M., Khelwatty, S. A., Seddon, A. M. and Modjtahedi, H., 2018, Oncotarget (9), pp 19662-19674
Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer
Arias-Pinilla, Gustavo A., Dalgleish, Angus G., Mudan, Satvinder, Bagwan, Izhar, Walker, Anthony J. and Modjtahedi, Helmout, 2018, Oncotarget (9), pp 19994-20007
Targeted delivery of doxorubicin into tumor cells by nanostructured lipid carriers conjugated to anti-EGFRvIII monoclonal antibody
Abdolahpour, Saeideh, Toliyat, Tayebeh, Omidfar, Kobra, Modjtahedi, Helmout, Wong, Albert J., Rasaee, Mohammad Javad, Kashanian, Susan and Paknejad, Maliheh, 2018, Artificial Cells, Nanomedicine, and Biotechnology (46), 1, pp 89-94
A novel recombinant anti-epidermal growth factor receptor peptide vaccine capable of active immunization and reduction of tumor volume in a mouse model
Asadi-Ghalehni, Majid, Rasaee, Mohamad Javad, RajabiBazl, Masoumeh, Khosravani, Masood, Motaghinejad, Majid, Javanmardi, Masoud, Khalili, Saeed, Modjtahedi, Helmout and Sadroddiny, Esmaeil, 2017, Microbiology and Immunology (61), 12, pp 531-538
Immunomodulatory effects of heat killed 'Mycobacterium obuense' on human blood dendritic cells
Bazzi, Samer, Modjtahedi, Helmout, Mudan, Satvinder, Achkar, Marcel, Akle, Charles and Bahr, Georges, 2017, Innate Immunity (23), 7, pp 592-605
Defining genome-wide expression and phenotypic contextual cues in macrophages generated by GM-CSF, M-CSF and heat-killed mycobacteria
Bazzi, Samer, El-Darzi, Emale, McDowell, Tina, Modjtahedi, Helmout, Mudan, Satvinder, Achkar, Marcel, Akle, Charles, Kadara, Humam and Bahr, Georges M, 2017, Frontiers in Immunology (8), pp 1253
Inhibitory effects of culinary herbs and spices on the growth of HCA-7 colorectal cancer cells and their COX-2 expression
Jaksevicius, Andrius, Carew, Mark, Mistry, Calli, Modjtahedi, Helmout and Opara, Elizabeth I, 2017, Nutrients (9), 10
Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
Stanley, Aryan, Ashrafi, G. Hossein, Seddon, Alan M. and Modjtahedi, Helmout, 2017, Scientific Reports (7), 3964
The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
Khelwatty, Said, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout, 2016, Oncotarget (8), 5, pp 7666-7677
Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of the HER inhibitors and cytotoxic drugs
Puvanenthiran, Soozana, Essapen, Sharadah, Seddon, Alan and Modjtahedi, Helmout, 2016, International Journal Of Oncology (49), 5, pp 1825-1838
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
Ioannou, Nikolaos, Seddon, Alan, Dalgleish, Angus, Mackintosh, David, Solca, Flavio and Modjtahedi, Helmout, 2016, International Journal Of Oncology (48), 3, pp 908-918
Analysis of the immunomodulatory properties of two heat-killed mycobacterial preparations in a human whole blood model
Bazzi, Samer, Modjtahedi, Helmout, Mudan, Satvinder, Akle, Charles and Bahr, Georges M, 2015, Immunobiology (220), 12, pp 1293-1304
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
Khelwatty, Said A., Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout, 2015, British Journal of Cancer (113), 7, pp 1010-1019
Epitope mapping of epidermal growth factor receptor (EGFR) monoclonal antibody and induction of growth-inhibitory polyclonal antibodies by vaccination with EGFR mimotope
Navari, Mohsen, Zare, Mehrak, Javanmardi, Masoud, Asadi-Ghalehni, Majid, Modjtahedi, Helmout and Rasaee, Mohammad Javed, 2014, Immunopharmacology and Immunotoxicology (36), 5, pp 309-315
Co-expression of HER family members in patients with Dukes' C and D colon cancer and their impacts on patient prognosis and survival.
Khelwatty, Said Abdullah, Essapen, Sharadah, Bagwan, Izhar, Green, Margaret, Seddon, Alan and Modjtahedi, Helmout, 2014, PloS one (9), 3, pp e91139
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.
Modjtahedi, Helmout, Cho, Byoung Chul, Michel, Martin C and Solca, Flavio, 2014, Naunyn-Schmiedeberg's archives of pharmacology
GA201: a novel humanized and glycoengineered anti-EGFR antibody
Modjtahedi, Helmout and Eccles, Suzanne, 2014, Clinical Cancer Research (20), 4, pp 1053-1054
Resveratrol 3-O-d-glucuronide and resveratrol 4'-O-d-glucuronide inhibit colon cancer cell growth: Evidence for a role of A3 adenosine receptors, cyclin D1 depletion, and G1 cell cycle arrest
Polycarpou, Elena, Meira, Lisiane B, Carrington, Simon, Tyrrell, Elizabeth, Modjtahedi, Helmout and Carew, Mark A, 2013, Molecular Nutrition and Food Research (57), 10, pp 1708-1717
Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
Ioannou, Nikolaos, Seddon, Alan M., Dalgleish, Angus, Mackintosh, David and Modjtahedi, Helmout, 2013, BMC Cancer (13), 41
Co-targeting of HER family members and IGF-IR in pancreatic cancer
Modjtahedi, Helmout, Ioannou, Nikolaos, Dalgleish, Angus, Mackintosh, David and Seddon, Alan M., 2013, International Journal Of Molecular Medicine (32), pp S40-S40
Prognostic significance and targeting of HER family in colorectal cancer
Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan Michael and Modjtahedi, Helmout, 2013, Frontiers in Bioscience (18), 2, pp 394-421
Therapeutic application of monoclonal antibodies in cancer: advances and challenges
Modjtahedi, Helmout, Ali, Sumaira and Essapen, Sharadah, 2012, British Medical Bulletin (104), 1, pp 41-59
Immunohistochemical discrimination of wild-type EGFR from EGFRvIII in fixed tumour specimens using anti-EGFR mAbs ICR9 and ICR10
Modjtahedi, H., Khelwatty, S.A., Kirk, R.S., Seddon, A.M., Essapen, S., Del Vecchio, C.A., Wong, A.J. and Eccles, S., 2012, British Journal of Cancer (106), pp 883-888
Expression pattern and targeting of HER family members and IGF-IR in pancreatic cancer
Ioannou, N., Seddon, A.M., Dalgleish, A., Mackintosh, D. and Modjtahedi, H., 2012, Frontiers in Bioscience (17), 1, pp 2698-2724
Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells
Ioannou, N, Dalgleish, A G, Seddon, A M, Mackintosh, D, Guertler, U, Solca, F and Modjtahedi, H, 2011, British Journal of Cancer (105), 10, pp 1554-1562
Growth response of human colorectal tumour cell lines to treatment with afatinib (BIBW2992), an irreversible erbB family blocker, and its association with expression of HER family members
Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan M. and Modjtahedi, Helmout, 2011, International Journal of Oncology (39), 2, pp 483-491
Periadventitial delivery of anti-EGF receptor antibody inhibits neointimal macrophage accumulation after angioplasty in a hypercholesterolaemic rabbit
Shafi, Shahida, Lamb, David, Modjtahedi, Helmout and Ferns, Gordon, 2010, International Journal Of Experimental Pathology (91), 3, pp 224-234
Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities
Modjtahedi, Helmout and Essapen, Sharadah, 2009, Anti-Cancer Drugs (20), 10, pp 851-855
Co-targeting the EGFR and IGF-IR with anti-EGFR monoclonal antibody ICR62 and the IGF-IR tyrosine kinase inhibitor NVP-AEW541 in colorectal cancer cells
Cunningham, Matthew P., Thomas, Hilary, Marks, Christopher, Green, Margaret, Fan, Zhen and Modjtahedi, Helmout, 2008, International Journal of Oncology (33), 5, pp 1107-1113
Responses of human colorectal tumor cells to treatment with the anti–epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib
Cunningham, Matthew P., Thomas, Hilary, Fan, Zhen and Modjtahedi, Helmout, 2006, Cancer Research (66), 15, pp 7708-7715
Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer
Cunningham, Matthew P., Essapen, Sharadah, Thomas, Hilary, Green, Margaret, Lovell, David P., Topham, Clare, Marks, Christopher and Modjtahedi, Helmout, 2005, International Journal of Oncology (27), 2, pp 317-325
The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathalogical parameters.
Essapen, Sharadah, Thomas, Hilary, Green, Margaret, De Vries, Corrine, Cook, Martin G., Marks, Christopher, Topham, Clare and Modjtahedi, Helmout, 2004, International Journal of Oncology (24), 2, pp 241-248
Targeting of cells expressing wild-type EGFR and type-III mutant EGFR (EGFRvIII) by anti EGFR MAb ICR62: A two-pronged attack for tumour therapy.
Modjtahedi, Helmout, Moscatello, David K., Box, Gary, Green, Margaret, Shotton, Christine, Lamb, David J., Reynolds, Lesley J., Wong, Albert J., Dean, Christopher, Thomas, Hilary and Eccles, Suzanne, 2003, International Journal of Cancer (105), 2, pp 273-280
Development of two novel monoclonal antibodies against overexpressed antigens on pancreatic cancer cells for use in diagnosis and therapy
Arias Pinilla, GA, Dalgleish, AG, Mudan, S, Bagwan, I, Walker, AJ and Modjtahedi, H(2018). In: 25th Biennial Congress of the European Association for Cancer Research (EACR25) : From Fundamental Insight to Rational Cancer Treatment, 30 Jun - 03 Jul 2018 :Amsterdam, The Netherlands
Acquired resistance to anti-EGFR mAb ICR62 or afatinib is accompanied by upregulation of the EGFR in colorectal cancer
Khelwatty, Said Abdullah, Essapen, Sharadah, Seddon, Alan M., Fan, Zhen and Modjtahedi, Helmout(2013). In: 104th Annual Meeting of the American Association for Cancer Research, 6-10 Apr 2013 :Washington, U.S.A.